Swedish Orphan Biovitrum AB (Sobi) has acquired the United States rights for Synagis (palivizumab), a drug developed for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV), from AstraZeneca.
It was reported yesterday that the deal is valued at around USD1.6bn. It also provides Biovitrum AB with the right to participate in payments from the US profits or losses for new medicine, MEDI8897, in development for RSV-induced lower respiratory tract infection. Under the deal, around 130 employees from AstraZeneca have joined Sobi, which commercialises Synagis in the United States.
AstraZeneca will continue to develop the product in collaboration with Sanofi's vaccines division, Sanofi Pasteur. Under the contract, AstraZeneca has secured USD1.0bn in cash and USD590m in ordinary shares of Biovitrum AB, which is equal to an ownership interest of 8%. AstraZeneca intends to retain the shares for one year.
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio
GSK and IQVIA expand vaccine track with local data to drive targeted public health action
AstraZeneca launches online platform to expand patient access to medications
Sanofi increases Sanofi Ventures funding by USD625m to boost biotech and digital health investments
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate